AMERICAN REBEL HOLDINGS INC (AREB): Entry into a Material Definitive Agreement

Nasdaq said it will delist multiple issuers’ securities from the Nasdaq Stock Market, including CERo Therapeutics Holdings, Bowen Acquisition Corp, Graphjet Technology, Blue Hat Interactive Entertainment Technology, X3 Holdings Co, Captivision Inc, Actelis Networks, American Rebel Holdings, Reviva Pharmaceuticals, Alchemy Investments Acquisition Corp 1, Bitcoin Depot, Inotiv, GoHealth, Functional Brands, Sleep Number, Smart Digital Group, and REE Automotive. Most were suspended in 2025-2026 and

SCWorx Corp. (Nasdaq: WORX) resumed trading on Nasdaq after regaining compliance with listing requirements. The company reported improved operating performance, with Q2 2026 revenue of $706,000 and gross profit up 83% YoY. Net loss declined significantly, and cash usage decreased. SCWorx aims to grow its healthcare customer base and leverage AI for data management.

Erez Asset Management acquired a 5.8% stake in Empire State Realty Trust (ESRT) for $43M, according to an SEC filing. ESRT's shares rose 4.7% on the news. Erez believes the shares are undervalued and has contacted ESRT leadership about capital allocation, operations, and a potential strategic review. The REIT's observation deck's NOI nearly halved, driving a $166M write-down, despite portfolio occupancy rising to 89.4%.

Chevron is restructuring its midstream operations in the Bakken and DJ Basin, selling assets to Hess Midstream LP (HESM) and replacing ownership with service contracts. The deal, expected to close by 2026, will reduce Chevron's debt by $3.7 billion but may result in a $3-4 billion after-tax loss. Hess Midstream gains independence and secures long-term contracts with Chevron.

Ultragenyx Pharmaceutical (RARE) shares rose 3.2% after agreeing to sell a Rare Pediatric Disease Priority Review Voucher for $210M, awarded following FDA approval of GENGLYCOS for glycogen storage disease. The company plans to use proceeds to support rare disease therapy development and advance profitability, according to Ultragenyx.

Ultragenyx Pharmaceutical (RARE) sold a Rare Pediatric Disease Priority Review Voucher for $210M, according to the company. Proceeds will support rare-disease programs. RARE shares rose 4% at the time of writing, despite broader market declines. This is Ultragenyx's third PRV sale, with previous sales in 2018 totaling $210.6M.